Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Stock Downgraded to 'In-Line' by Evercore ISI

NEW YORK ­– Investment banking firm Evercore ISI has downgraded shares of Illumina to an In Line rating, with a price target of $340.

"We are downgrading Illumina to In Line as we see risks and upside surprises as being fairly balanced at current levels," analyst Vijay Kumar wrote in a research note.

"While we are huge fans of Illumina as a fundamental, secular growth company longer term, current valuation causes us to move to the sidelines," he added.

Previously, Evercore had rated the shares at Outperform with a price target of $330.

Kumar said Illumina "had a challenging 2019, with a few curveballs being thrown at the company," including declines in its microarray and direct-to-consumer business, headwinds in China, and delays in population genomics projects. Growth "never materialized," leading to a year of "misses and lowered guidance," Kumar wrote. "As we look towards 2020, we think the company is likely to start the year with a conservative outlook."

In morning trading on the Nasdaq, shares of Illumina were down 1 percent at $328.14.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.